4RAM P A,WAXMAN D J.Interaction of growth hormne-activated STATS witll SH2-containing phosphatase SHP-1 and nuclear JAK2 tyrosine kinase[J].J Riov Chem,1997,272:17694-17702. 被引量：1
5LEVINE R L,LORIAUX M,HUNTLY B J,et al.The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia,but not in acute lymphoblastie leukemia or chronic lymphocytic leukemia[J].Blood,2005,106:3377-3779. 被引量：1
6PIERI L,BOGANI C,GUGLIELMELLI P,et al.The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils from patients with polycythemia vera[J].Haematologica,2009,94:1537-1545. 被引量：1
7YHIM H Y,KIM H S,SOHN J Y,et al.JAK2 V617F-positive essential thrombocythemia in a patient with Klinefelter syndrome:a case report[J].Cancer Genet Cytogenet,2010,198:162-165. 被引量：1
8TEFFERI A.Mutational analysis in BCR-ABL-negative classic myeloproliferative neoplasms:impact on prognosis and therapeutic choices[J].Leuk Lymphoma,2010,51:576-582. 被引量：1
9OLCAYDU D,HARUTYUNYAN A,JGER R,et al.A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms[J].Nat Genet,2009,41:450-454. 被引量：1
10NUSSENZVEIG R H,SWIERCZEK S I,JELINEK J,et al.Polycythemia vera is not initiated by JAK2V617F mutation[J].Exp Hematol,2007,35:32-38. 被引量：1
